Licensing Deals The company earlier this year announced that it had signed non-exclusive voluntary licensing agreements for the drug with five generic manufacturers in India in a bid to accelerate availability in more than 100 low- and middle-income countries following approvals or emergency authorization by local regulatory agencies.
Potentially the drug could be very cheap to manufacture and available at a low cost in developing nations, benefiting millions of people, Andrew Hill, a senior research fellow at the University of Liverpool, wrote in an email. “This could be a major advance in the treatment of Covid-19," he said.